TL;DR: PBM rebates can cut net drug costs by about 10% to 20% in some employer plans, but only when the employer can see, verify, and receive the full value. In 2025, more employers moved to pass-through Rebate models to improve clarity. In 2026, added reform pressure is pushing contracts, reporting, and audit rights into sharper focus.
Key Takeaways
- A large Rebate doesn’t always mean a lower total drug cost.
- Pass-through models can improve visibility and help employers keep more savings.
- Rebate value should match actual drug use, not broad estimates.
- Audits matter because hidden fees, exclusions, and weak definitions can erase expected savings.
- The best pharmacy strategy balances cost, member experience, and long-Term plan health.
Pharmacy spend can feel like a black box. You see the invoice, you hear the Rebate promise, and then months later a payment shows up that may or may not match what your plan used.
That gap is where employers lose money. Clear contract terms, strong reporting, and regular audits turn Rebate talk into measurable outcomes.
Why PBM rebates still matter to employers in 2025 and 2026 #
A PBM Rebate is money a drug manufacturer pays, usually in exchange for favorable Formulary placement. The PBM negotiates that payment, then shares some or all of it with the health plan, based on the contract.
That sounds simple. It isn’t.
For employers, the real issue is Net Cost, not the size of the Rebate check. A drug with a high list price and a large Rebate may still cost more than a lower-priced option with little or no Rebate. Finance teams need that distinction because gross spend can look worse than final spend. HR teams need it because employee access and disruption also matter.
This quick comparison helps frame the difference:
| Cost view | What it shows | What it can miss |
|---|---|---|
| Gross drug cost | The price before rebates and discounts | Whether the plan gets money back later |
| Rebate value | Manufacturer payments tied to contract terms | Hidden offsets, exclusions, or delays |
| Net drug cost | Gross cost minus verified rebates and discounts | Member disruption if the Formulary strategy is weak |
The takeaway is simple. Rebates matter, but Net Cost matters more.
That is why employers in 2025 kept pushing for more visible Rebate arrangements, better claim reporting, and less dependence on opaque Spread Pricing. Market concentration still gives a few PBMs huge influence over pricing and data. As a result, plan sponsors have become more direct about contract terms and audit rights.
What a Rebate lowers, and what it does not #
A Rebate can lower the employer’s final pharmacy spend. It usually does not lower what a member pays at the pharmacy counter unless the plan uses point-of-sale Rebate sharing.
That distinction matters. A plan can report strong Rebate income while employees still face high Coinsurance based on list price. For a family managing a Specialty Drug or a chronic condition, that gap is more than an accounting issue. It shapes whether treatment feels affordable.
High rebates can also distract from better choices. A lower-cost generic, biosimilar, or preferred alternative may produce a better net outcome even if the Rebate is smaller.
A Rebate is helpful only when it improves the plan’s true cost position and supports the people using the plan.
Why transparency is the real driver of savings #
Transparency is what turns Rebate promises into cash the employer can trust.
If you can’t see contract language, claims detail, Rebate formulas, fees, and payment timing, you can’t confirm value. You’re left with totals on a report and no clean way to connect them to actual utilization.
Common blind spots include retained rebates, administrative fee offsets, loose definitions of “specialty,” and bundled guarantees that hide weak performance in one area behind stronger numbers in another. A PBM may meet an overall guarantee while missing the Rebate target on a key drug class.
That is why many employers now pair pharmacy reviews with broader data work such as actuarial analysis for benefits. When claims, trend, and Rebate data line up, leadership can make decisions with more confidence and better ROR (Return on Relationship).
How pass-through Rebate models help employers keep more of the savings #
A pass-through Rebate model is built around one core promise: the PBM passes 100% of negotiated rebates and related discounts back to the plan sponsor, according to the contract.
For employers, that model often improves budgeting and accountability. Instead of wondering how much Rebate value stayed with the PBM, the employer sees the flow of dollars more clearly.
Traditional arrangements can be harder to read. A PBM may retain part of the Rebate directly, or keep value through pricing methods, fees, or contract language that offsets one concession with another. The employer may still get a Rebate check, but not the full savings picture.
In 2025, more employers moved toward pass-through terms because pharmacy spend became too large to manage on trust alone. In 2026, federal reform pressure grew even stronger. New rules are pushing the market toward fuller Rebate pass-through, more regular reporting, and clearer audit rights over the next few plan years.
That doesn’t mean every pass-through deal is automatically better. It does mean the employer has a cleaner starting point.
What to ask for in a pass-through PBM contract #
Plain contract language matters more than sales language. If the wording is vague, the savings are vague too.
Look for terms that clearly define:
- 100% Rebate pass-through, including all manufacturer-paid rebates, fees, and discounts tied to claims
- No hidden Spread Pricing, with transparent pharmacy reimbursement and dispensing fees
- Claim-level reporting, ideally with NDC-level detail when available
- Rebate payment timing, including quarterly schedules and reconciliation rules
- Audit rights, including access to an independent auditor and supporting data
- Clear definitions for brand, specialty, Formulary exclusions, and manufacturer administrative fees
Those points may sound technical, but they affect real dollars. They also affect trust across leadership teams.
When pass-through is better, and when it still needs a closer look #
Pass-through is often stronger for transparency. Still, it is not always the lowest-cost option.
A contract can pass through rebates and still underperform if Specialty Drug pricing is weak, clinical management is poor, or network terms inflate ingredient costs. In other words, Rebate transparency helps, but it doesn’t solve every pharmacy issue.
Employers should judge the full pharmacy strategy. That includes Formulary design, specialty management, point-of-sale pricing, prior authorization standards, and member support. Savings on paper don’t mean much if employee friction rises and avoidable spend keeps growing.
How to audit PBM rebates and make sure they match actual utilization #
A Rebate audit answers one basic question: did the plan receive what the contract promised, based on the drugs members actually used?
For Self-Funded employers, that question should come up often. Annual reviews are common, but many plans benefit from more frequent reporting and mid-year checks, especially when Specialty Drug spend is rising fast.
The process does not need to be mysterious. It needs to be disciplined.
Start with the contract. Confirm the exact Rebate formula, the guarantee period, and the definition of eligible claims. Then compare those terms against paid claims, Formulary status, exclusion rules, and the timing of manufacturer payments. If the contract says a class of drugs is Rebate eligible, the utilization file should show whether those drugs were used and whether the related Rebate value appeared in the payment cycle.
This is where benchmarking helps. Clean comparisons make it easier to spot whether your Rebate yield is reasonable for your size, utilization mix, and drug classes. Employers that want better visibility into plan comparisons often benefit from custom Insight benchmarking results to frame what is normal and what deserves a closer review.
The data points that matter most in a Rebate audit #
A strong audit relies on detail, not summary sheets.
The most useful data points include claim-level utilization, NDC-level detail when available, Formulary placement, Specialty Drug mix, guarantee periods, effective dates, excluded claims, manufacturer payment timing, and the full reconciliation method.
Finance teams need this detail to validate whether promised savings showed up in the correct period. HR teams need it because exclusions, Formulary shifts, and specialty definitions can affect employee access and communication. Executive leadership needs it because pharmacy strategy is now a budget and workforce issue at the same time.
Specialty drugs deserve extra attention because a small number of claimants can drive a large share of spend. For added context on this trend, JA’s article on specialty pharmacy spending trends shows why these claims can quickly change the Rebate picture.
Red flags that may point to missed savings or weak contract terms #
Some warning signs show up early.
Delayed Rebate payments are one. Unexplained exclusions are another. So are inconsistent reporting periods, Rebate guarantees that are hard to measure, and contract language that gives the PBM room to redefine key terms after the fact.
Large gaps between expected and actual savings should always trigger a review. The same goes for reports that show Rebate totals without enough utilization detail to trace where those dollars came from.
If you can’t tie Rebate dollars back to claims activity, you don’t have proof of savings. You have a summary.
A smarter PBM Rebate strategy looks beyond rebates alone #
The best pharmacy strategy is larger than rebates. It balances transparency, member experience, clinical quality, and total plan cost.
That balance matters because employees don’t feel “net savings” in the abstract. They feel copays, prior authorizations, Step Therapy rules, Specialty Drug access, and how well the plan explains their options. A strong contract should support both the business and the people using the plan.
How leadership teams can align HR, finance, and advisors around pharmacy savings #
Each group sees PBM performance through a different lens.
HR focuses on employee impact, communication, and disruption. Finance focuses on predictability, trend, and Net Cost. The C-suite looks at strategy, risk, and long-Term outcomes.
A shared review process closes those gaps. When all three groups review Rebate terms, utilization patterns, and member effects together, decisions get better. That is where a strong partner adds knowledge, not noise.
Simple next steps employers can take before their next PBM renewal #
Before the next renewal cycle, keep the review practical:
- Review current Rebate language and define what “100% pass-through” actually includes.
- Confirm whether the PBM arrangement uses Spread Pricing anywhere in the contract.
- Request detailed reporting with claim-level support, not summary totals alone.
- Compare Rebate payments to real utilization and Specialty Drug mix.
- Test audit rights before you need them.
- Measure total Net Cost, not rebates in isolation.
Employers that start early will be in a stronger position as the transparency push continues through 2026 and beyond.
PBM rebates can lower net drug costs, but only when the employer can see the full picture. Pass-through models gained ground in 2025 because employers wanted cleaner access to savings, and audits remain the best way to confirm those dollars match real utilization.
The strongest pharmacy strategy does more than produce a Rebate check. It creates clarity, supports employees, and gives leadership measurable outcomes instead of guesswork.
